News

Lipid nanoparticle drug system targets COVID-19 associated lung damage
A new drug delivery system developed by researchers at the University of Hawaiʻi at Mānoa John A. Burns School of Medicine ...
ascopubs.org1d
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non ...
FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full ...
ascopubs.org2d
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor ...
patients with previous or current evidence of interstitial lung disease (ILD) were excluded. An Eastern Cooperative Oncology Group performance status of 0 or 1 was required at screening. Patients ...